@article{TGH3610,
author = {Linda X. Jin and Ryan C. Fields},
title = {Survival in lymph node-negative gastric cancer: the Western experience},
journal = {Translational Gastroenterology and Hepatology},
volume = {1},
number = {5},
year = {2016},
keywords = {},
abstract = {Lymph node status is the strongest prognostic indicator for survival after gastrectomy for gastric adenocarcinoma (GAC) (1). However, for patients who undergo resection and are deemed to be ‘node-negative’ based on pathologic exam, the relevant prognostic indicators and guidelines for adjuvant therapy remain unclear. Our group has recently published the long-term survival results of a large, multi-institutional database of North American patients undergoing gastrectomy for GAC, of which 317 patients were lymph node-negative (2). To date, it is the largest published series of a Western experience with node-negative GAC. The median follow-up time was significant at 68 months, and the overall recurrence rate was 17%. We evaluated endpoints of time to recurrence and overall survival (OS). Our data showed that greater depth of tumor invasion (indicated by T-stage) was independently significant in predicting shorter time to recurrence in a competing risks regression model whereas OS was negatively impacted by higher tumor stage, lymphovascular invasion, signet ring histology, and having less than 15 nodes examined.},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/3610}
}